<DOC>
	<DOCNO>NCT02602925</DOCNO>
	<brief_summary>Rationale/hypothesis : Moderate-to-severe psoriasis treat biologics . Objective To investigate whether dose biologics reduce patient psoriasis stable disease . Study design : A pragmatic , multicentre , randomize , control , non-inferiority study cost-effectiveness analysis . Study population : Patients disease remission use normal dose biologics . Intervention : 120 patient randomize two group : ( 1 ) dose reduction ( 2 ) normal dose . Main study parameters/endpoints : The primary outcome clinical effectiveness . Secondary outcome : health-related quality life ( HRQoL ) , number time disease flare , cost , health status , anti-drug antibody formation serious adverse event</brief_summary>
	<brief_title>Tight Control Dose Reductions Biologics Psoriasis Patients With Low Disease Activity</brief_title>
	<detailed_description>Rationale/hypothesis : Moderate-to-severe psoriasis treat biologics . These drug significantly improve quality life psoriasis patient , expensive drug use efficiently possible . In addition , long-term safety profile probably improve patient receive low effective dose . Objective To investigate whether dose biologics reduce patient psoriasis stable disease : Is dose reduction non-inferior current practice regard clinical effectiveness ? Secondary aim : investigate influence dose taper quality life , whether predictor successful dose reduction , determine cost-effectiveness dose reduction . Study design : A pragmatic , multicentre , randomize , control , non-inferiority study cost-effectiveness analysis . Study population : Patients use biologic least 6 month ( etanercept , adalimumab , ustekinumab ) include long-term stable low disease activity . Low disease activity define PASI score ( Psoriasis Area Activity Score ) &lt; 5 health-related quality life score ≤5 ( Dermatology Quality life index : DLQI ) . Intervention : 120 patient randomize two group : ( 1 ) dose reduction guide PASI DLQI ( n=60 , intervention ) ( 2 ) maintenance normal dosage ( n=60 , usual care ) . Main study parameters/endpoints : The primary outcome clinical effectiveness . Secondary outcome : health-related quality life ( HRQoL ) , number time disease flare , cost , health status , anti-drug antibody formation serious adverse event</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Sustained low disease activity describe dose advised label . Established diagnosis plaque psoriasis . Receiving treatment adalimumab , etanercept , ustekinumab least 6 month . * Age ≥18 year . Ability understand inform consent , read answer questionnaire . Psoriasis main reason biologic prescription ( e.g . patient RA psoriasis , RA main reason biologic ) . Concomitant use immunosuppressant methotrexate acitretin psoriasis . Severe comorbidities short lifeexpectancy ( e.g . metastasize tumour ) . Presumed inability follow study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>